ID | 64370 |
JaLCDOI | |
FullText URL | |
Author |
Higuchi, Chigusa
Health Service Center, Okayama University
|
Abstract | The inactivated coronavirus disease 2019 vaccine CoronaVac has not been approved in Japan. Little information is available on cases in Japan in which an approved mRNA vaccine was administered as the initial (first or second) dose after two doses of CoronaVac. Furthermore, the safety and efficacy of this combination are not established. We here evaluated the safety and efficacy in a patient who showed an antibody response to an approved vaccine, mRNA-1273, after a previous vaccination with CoronaVac. The adverse events consisted of only mild local and systemic common reactions and were transient. In addition, a strong and persistent antibody response was observed.
|
Keywords | coronavirus disease 2019
severe acute respiratory syndrome coronavirus 2
vaccine
adverse events
antibody response
|
Amo Type | Case Report
|
Publication Title |
Acta Medica Okayama
|
Published Date | 2023-02
|
Volume | volume77
|
Issue | issue1
|
Publisher | Okayama University Medical School
|
Start Page | 105
|
End Page | 109
|
ISSN | 0386-300X
|
NCID | AA00508441
|
Content Type |
Journal Article
|
language |
English
|
Copyright Holders | Copyright Ⓒ 2023 by Okayama University Medical School
|
File Version | publisher
|
Refereed |
True
|
PubMed ID | |
Web of Science KeyUT |